UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042838
Receipt number R000048904
Scientific Title Observational study of the relationship between tissue preservation status and success rate of Oncomine Dx Target Test Multi-CDx system in lung cancer
Date of disclosure of the study information 2020/12/25
Last modified on 2022/08/14 11:41:37

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Observational study of the relationship between tissue preservation status and success rate of Oncomine Dx Target Test Multi-CDx system in lung cancer

Acronym

Observational study of the relationship between tissue preservation status and success rate of Oncomine DxTT in lung cancer

Scientific Title

Observational study of the relationship between tissue preservation status and success rate of Oncomine Dx Target Test Multi-CDx system in lung cancer

Scientific Title:Acronym

Observational study of the relationship between tissue preservation status and success rate of Oncomine DxTT in lung cancer

Region

Japan


Condition

Condition

Non-small cell lung cancer (NSCLC)

Classification by specialty

Pneumology Hematology and clinical oncology Chest surgery

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To clarify optimal method for storing surgical specimens for NGS by comparing the Oncomine Dx Target Test Multi-CDx system results when the excised specimen of the same patient is fixed with formalin immediately after excision and the excised specimen is stored in a refrigerator and fixed with formalin after surgery.

Basic objectives2

Others

Basic objectives -Others

Success rate of gene mutation measurement

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Nucleic acid recovery amount and analysis results by Oncomine Dx Target Test Multi-CDx system

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Cases of lung cancer resection surgery performed at the Osaka International Cancer Institute after February 2020
2.Cases in which there are both samples that were formalin-fixed immediately after lung cancer resection and samples that were refrigerated and formalin-fixed after surgery.
3.Written informed consent after sufficient explanation.

Key exclusion criteria

None

Target sample size

15


Research contact person

Name of lead principal investigator

1st name Kazumi
Middle name
Last name Nishino

Organization

Osaka International Cancer Institute

Division name

Thoracic Oncology

Zip code

541-8567

Address

3-1-69 Otemae, Chuo-ku Osaka city, Japan

TEL

06-6945-1181

Email

kazumi.nishino@oici.jp


Public contact

Name of contact person

1st name Kei
Middle name
Last name Kunimasa

Organization

Osaka International Cancer Institute

Division name

Thoracic Oncology

Zip code

5418567

Address

3-1-69 Otemae, Chuo-ku Osaka city, Japan

TEL

0669451181

Homepage URL


Email

kei.kunimasa@oici.jp


Sponsor or person

Institute

Department of Thoracic Oncology,
Osaka International Cancer Institute

Institute

Department

Personal name



Funding Source

Organization

Department of Thoracic Oncology,
Osaka International Cancer Institute

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Osaka International Cancer Institute

Address

3-1-69 Otemae, Chuo-ku Osaka city, Japan

Tel

06-6945-1181

Email

rinri01@opho.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大阪国際がんセンター(大阪府)


Other administrative information

Date of disclosure of the study information

2020 Year 12 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

17

Results


Results date posted


Results Delayed

Delay expected

Results Delay Reason

in the process of being written

Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2020 Year 09 Month 27 Day

Date of IRB

2020 Year 09 Month 29 Day

Anticipated trial start date

2020 Year 12 Month 25 Day

Last follow-up date

2021 Year 09 Month 30 Day

Date of closure to data entry

2021 Year 11 Month 20 Day

Date trial data considered complete

2021 Year 11 Month 28 Day

Date analysis concluded



Other

Other related information

Observational study


Management information

Registered date

2020 Year 12 Month 24 Day

Last modified on

2022 Year 08 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048904


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name